Rhythm Pharmaceuticals Inc. Common Stock (RYTM)

FairStock Score: 25/100 — RISKY

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.47, providing financial flexibility
• Altman Z-Score of 13.3 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 36.9% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration

AI Analysis

Rhythm Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $5.8 billion. Revenue stands at $217 million, though the company is currently unprofitable. From a quality standpoint, Rhythm shows Altman Z-Score of 13.3 confirms fortress-level solvency and negative ROE indicating losses. Growth dynamics show revenue growing at 36.9% and profit growth of -9.7%. Our composite FairStock Score of 25/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Rhythm's 37% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer